Author

Elaine Eisenbeisz

Institution: Parker Institute for Cancer Immunotherapy

Observed institutions: WakeMed, Parker Institute for Cancer Immunotherapy

OpenAlex ID: A5046750796

Hypofractionated Versus Standard Fractionated Proton-beam Therapy for Low-risk Prostate Cancer

2015 · Carlos E. Vargas, William F. Hartsell, et al. · American Journal of Clinical Oncology · 42

Comparison of Transcutaneous and Serum Bilirubin Measurements in Neonates 30 to 34 JOURNAL/ancr/04.03/00149525-201804000-00012/12FSM1/v/2023-07-21T043933Z/r/image-gif Weeks' Gestation Before, During, and After Phototherapy

2018 · Amy Jnah, Desi M. Newberry, et al. · Advances in Neonatal Care · 25

559 Biomarker correlates of clinical response with FLT3L/nivo backbone treatment in the multi-cohort phase 1 PORTER platform trial in metastatic castration-resistant prostate cancer patients

2022 · Kristin Shotts, Timothy Howes, et al. · Regular and Young Investigator Award Abstracts

555 Clinical and pharmacodynamic biomarker results from PORTER, a multi-cohort phase 1 platform trial of combination immunotherapy for metastatic castration-resistant prostate cancer patients

2022 · Matthew Galsky, Karen Autio, et al. · Regular and Young Investigator Award Abstracts

Works count: 4

Citation count: 67

H-index: 2

I10-index: 2